Combined Use of Subclinical Hydroxyurea and CHK1 Inhibitor Effectively Controls Melanoma and Lung Cancer Progression, With Reduced Normal Tissue Toxicity Compared to Gemcitabine

Molecular Oncology - Netherlands
doi 10.1002/1878-0261.12497
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Gemcitabine Combined With Capecitabine Compared to Gemcitabine With or Without Erlotinib as First-Line Chemotherapy in Patients With Advanced Pancreatic Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2014English

Phase III Non-Inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer

EClinicalMedicine
Medicine
2019English

A Case of Late-Onset Gemcitabine Lung Toxicity

Clinical Medicine Insights: Oncology
Oncology
2011English

Metastatic Non-Small-Cell Lung Cancer and the Use of Gemcitabine During Pregnancy

Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2008English

Vorinostat Combined With DNMTi Epigenetically Controls the Proliferation of Lung Cancer Cells A549

International Journal of Science and Research (IJSR)
2017English

Topotecan Synergizes With CHEK1 (CHK1) Inhibitor to Induce Apoptosis in Ovarian Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Toxicity of Hydroxyurea in Rats and Dogs

Toxicologic Pathology
Forensic MedicineToxicologyPathologyCell BiologyMolecular Biology
2014English

Progression and Metastasis of Lung Cancer

Cancer and Metastasis Reviews
Cancer ResearchOncology
2016English

Patients With Peripheral Arterial Disease Exhibit Reduced Joint Powers Compared to Velocity-Matched Controls

Gait and Posture
Sports ScienceOrthopedicsSports MedicineRehabilitationBiophysics
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy